Drug Search Results
More Filters [+]

Odiparcil

Alternative Names: odiparcil, sb-424323, sb424323, sb 424323, odiparci
Latest Update: 2024-12-17
Latest Update Note: News Article

Product Description

Mechanisms of Action: Thrombin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Mucopolysaccharidosis VI *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Odiparcil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mucopolysaccharidosis VI|Atrial Fibrillation|Thromboembolism|Pulmonary Embolism|Venous Thromboembolism|Embolism and Thrombosis|Venous Thrombosis|Mucopolysaccharidosis

Phase 1: Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-002158-35

P2

Completed

Mucopolysaccharidosis

2019-10-22

iMProveS

P2

Completed

Mucopolysaccharidosis VI

2019-09-24

23%

2005-001256-20

P2

Completed

Atrial Fibrillation

2006-12-28

NCT00240643

P2

Completed

Atrial Fibrillation

2006-12-01

Recent News Events